Veritas Intercontinental

What Veritas Intercontinental does

Veritas Intercontinental S.L.U. is a Madrid-headquartered direct-to-consumer genetic testing company founded in 2018 as the international operating arm of the Veritas genetics brand (originating from Veritas Genetics, founded in 2014 by Dr. George Church of Harvard Medical School). The company offers 18 products across three categories — preventive medicine (myGenome WGS, myGeneticRisk, myHealthScore, myPharma), reproductive/perinatal medicine (myPrenatal NIPT, myNewborn screening, myBabyHealth, qCarrier, PregnancyLoss, PrenatalWES, ArrayCGH Prenatal, ThromboRisk), and diagnostic genomics (CardioRisk, CancerRisk, GenomeDx, ExomeDx, Targeted Panels) — all requiring physician prescription and bundled with pre- and post-test genetic counseling. Its core technology is Whole Genome and Exome Sequencing on Illumina NGS platforms, with a proprietary data management and curation system (including the open-source Arvados platform co-developed by Veritas, which administers approximately 20 Petabytes of genomic data) and AI/ML tooling for variant interpretation.

The business model is direct-to-consumer one-time-payment e-commerce (veritasint.com with localized storefronts across Europe and LATAM) supplemented by a medical-professional referral channel feeding elective genomic screening into health check-up units. All tests are sold through self-service online purchase with mandatory genetic counseling. Geographic footprint spans Spain, UK, Italy, Portugal, Brazil, Colombia, Mexico, Ecuador, Argentina, UAE, and Japan, supported by regional subsidiaries and laboratories. In March 2022 the company was acquired by LetsGetChecked, a global health solutions company, and in January 2025 it acquired NIMGenetics to broaden its genetics portfolio. Veritas is privately held with no disclosed revenue; headcount is 11–50 employees.

Name

Veritas Intercontinental

Legal name

Veritas Intercontinental S.L.U.

Website

https://veritasint.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Veritas Intercontinental is a Madrid-based direct-to-consumer genetic testing company offering physician-prescribed whole genome, exome, and panel-based tests across preventive, reproductive, and diagnostic genomics in Europe, LATAM, the Middle East, and Japan, operating as a LetsGetChecked subsidiary.

Ownership category

akta.pro rank

Product category

Clinical Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic Counseling & Prenatal Testing Telehealth (carrier screening, NIPT counseling) (HLALAHAK), Population Genomics & Preventive Precision Health Programs (HLAAANAL)

Keywords

• Genetic testing services
• Whole genome sequencing
• Preventive genomics
• Prenatal genetic screening
• Clinical genetic diagnostics

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Direct-to-Consumer Genetic Testing: Veritas generates revenue through direct sales of genetic testing kits and services to individual consumers through its e-commerce platform. All genetic tests require medical prescription and include pre- and post-test genetic counseling as part of the service.
2. Preventive Medicine Genetic Services: Whole genome sequencing-based services for disease prevention including myGenome, myGeneticRisk, myHealthScore, and myPharma tests for pharmacogenomic analysis
3. Perinatal Medicine Services: Non-invasive prenatal testing (NIPT), newborn screening, and reproductive genetic testing services including myPrenatal, myNewborn, myBabyHealth, and carrier screening
4. Diagnostic Genomics Services: Clinical diagnostic genetic testing for hereditary cardiovascular disease (CardioRisk), hereditary cancer risk (CancerRisk), and whole genome/exome sequencing for complex medical cases (GenomeDx, ExomeDx)
5. Genetic Counseling Services: Pre- and post-test genetic counseling services included with all genetic tests to evaluate test suitability, interpret results, and design action plans

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Veritas Intercontinental provides whole genome and exome sequencing-based genetic testing services directly to consumers through physician-prescribed test kits. The portfolio spans preventive medicine (myGenome whole genome sequencing, polygenic risk screening, pharmacogenomics), perinatal medicine (non-invasive prenatal testing, newborn screening, carrier screening), and diagnostic genomics (hereditary cardiovascular, hereditary cancer, and whole genome/exome diagnostic testing), with mandatory pre- and post-test genetic counseling included.

Product overview

Veritas Intercontinental offers a comprehensive genomics platform with three main service areas: Preventive Medicine (led by myGenome whole genome sequencing), Perinatal Medicine (myPrenatal NIPT and myNewborn screening), and Diagnostic Genomics (CardioRisk, CancerRisk, GenomeDx, ExomeDx). All services require genetic counseling and medical prescription. The portfolio includes 18 distinct products spanning preventive, reproductive, and diagnostic genetics, unified by whole exome and genome sequencing technology that generates lifetime-accessible genetic data with re-analysis capabilities as science advances.

Differentiator

Problem solved

Functional benefit

Brands

• myGenome: The most comprehensive genetic service based on whole genome sequencing for disease prevention and healthcare.
• myGeneticRisk
• myHealthScore
• myPharma
• myPrenatal
• myNewborn
• myBabyHealth
• qCarrier
• PregnancyLoss
• PrenatalWES
• ArrayCGH Prenatal
• ThromboRisk
• CardioRisk
• CancerRisk
• GenomeDx
• ExomeDx
• Targeted Panels
• Genetic Counselling

Products and services

• myGenome Whole genome sequencing service that decodes all 6 billion letters of an individual's DNA, generating a complete genetic dataset that can be reanalysed as science advances; targets health-conscious individuals seeking preventive genomic insights, with clinical interpretation and pharmacogenomic reporting.
• myGeneticRisk Genetic test that assesses risk for common diseases, including cardiovascular conditions and cancer, through polygenic risk screening; for health-conscious individuals seeking to understand their hereditary predisposition profile.
• myHealthScore Health scoring system that provides personalized health metrics based on an individual's genetic predispositions and lifestyle factors; for consumers seeking a quantified view of inherited health risks.
• myPharma Pharmacogenomic test, based on clinical guidelines, that analyzes how an individual's genetic variants affect drug metabolism and response; for patients and physicians seeking to optimize medication selection and dosing.
• myPrenatal Non-invasive prenatal test (NIPT) that studies the most frequent chromosomal abnormalities from week 10 of pregnancy; for pregnant women seeking reassurance on fetal chromosomal health without invasive procedures.
• myNewborn Neonatal genetic screening test for the detection of diseases with onset in early childhood; for parents of newborns seeking early identification of treatable hereditary conditions.
• myBabyHealth Combined bundle that brings together myPrenatal and myNewborn to provide the most complete genetic care for babies, covering both prenatal and neonatal hereditary disease screening.
• qCarrier Carrier screening test to identify whether individuals carry genetic variants for monogenic recessive diseases that could be transmitted to offspring; for couples planning pregnancy.
• PregnancyLoss Genetic study of chromosomal abnormalities associated with spontaneous termination of pregnancy, to identify underlying genetic causes of pregnancy loss.
• PrenatalWES Prenatal whole exome sequencing for detailed genetic analysis during pregnancy when specific fetal conditions are suspected; for high-risk pregnancies requiring comprehensive molecular investigation.
• ArrayCGH Prenatal Prenatal comparative genomic hybridization (CGH) array for detection of chromosomal microdeletions and microduplications during pregnancy.
• ThromboRisk Genetic test that assesses thrombosis risk by identifying genetic variants that increase susceptibility to blood clots; for individuals with personal or family history of thrombotic events.
• CardioRisk Hereditary cardiovascular disease risk assessment using genetic analysis to identify predispositions to cardiac conditions including inherited cardiomyopathies and arrhythmia syndromes.
• CancerRisk Hereditary cancer risk assessment that identifies genetic variants associated with increased susceptibility to cancers such as breast, ovarian, colorectal, and other hereditary cancer syndromes.
• GenomeDx Whole genome and exome sequencing service for patients with complex medical history or symptoms suggesting a genetic origin, used to identify the underlying genetic cause of disease.
• ExomeDx Targeted whole exome sequencing for detailed analysis of protein-coding regions to identify genetic variants associated with specific clinical conditions; used as a diagnostic aid by referring physicians.
• Targeted Panels Customized virtual panel tests designed for detection of genetic diseases across different medical areas, configured for specific clinical indications as prescribed by a physician.
• Genetic Counselling Pre- and post-test genetic counseling service that assesses test suitability, interprets results, and designs personalized action plans for healthcare management; bundled with every Veritas test.

Quantifiable outcome

• 17% of people have genetic variants that increase disease risk
• +6 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature5 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• LetsGetCheckedflagshipStrategic or Co-development Partner · 1 March 2022In March 2022, Veritas announced joining LetsGetChecked, a global health solutions company. This acquisition brought Veritas under the LetsGetChecked umbrella, expanding its global health solutions capabilities.
• IlluminacoreTechnology or IntegrationVeritas utilizes Illumina sequencing technology in its laboratories. A new laboratory in Spain, inaugurated in the second semester of 2020, features state-of-the-art Illumina technology for whole genome and exome sequencing.
• Harvard Medical School - Personal Genome ProjectcoreStrategic or Co-development PartnerVeritas Genetics was co-founded by leaders of Harvard Medical School's Personal Genome Project, including Dr. George Church, one of the pioneers of the Human Genome Project. The company leverages knowledge and expertise from this academic partnership.
• Clínica Universidad de NavarracoreStrategic or Co-development PartnerAcademic medical center conducting research using Veritas Intercontinental's myGenome test. Published results of retrospective study integrating elective genomic testing into medical check-up unit, sequencing whole genomes of 400 unselected adults.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Nebula Genomics: WGS-based personal genomics company co-founded by George Church. Strong scientific overlap with Veritas given Church's dual involvement, though smaller commercial scale.

Direct peers

• 23andMe: Direct-to-consumer genetic testing pioneer offering genotyping-based health and ancestry reports. Closely comparable DTC motion and international footprint, though Veritas differentiates via WGS versus 23andMe's genotyping array.
• Invitae: Clinical genetic testing company offering hereditary cancer, cardiovascular, reproductive, and rare disease panels. Comparable across diagnostic and reproductive genetics pillars, with deeper payer infrastructure.
• Natera: Specialized reproductive and oncology genetics company, leader in NIPT (Panorama) and MRD oncology testing. Direct competitor in the perinatal medicine pillar and increasingly in oncology diagnostics.
• Myriad Genetics: Established clinical genetics company with leading hereditary cancer (BRACAnalysis) and pharmacogenomic tests. Comparable across diagnostic genomics and pharmacogenomics pillars.
• Color Genomics: Population genomics and hereditary cancer testing company serving employers, health systems, and consumers. Comparable across preventive and hereditary risk pillars with strong B2B health-system channel.
• Dante Labs: Direct-to-consumer whole genome sequencing company with international presence. Most direct head-to-head competitor on WGS-based DTC offerings globally.

Broad incumbents

• LetsGetChecked: Parent company of Veritas Intercontinental since March 2022. Operates a broader at-home health testing platform (sexual health, wellness, chronic condition monitoring) into which Veritas genetics is integrated.
• Ancestry: Large consumer genomics platform historically focused on ancestry but expanding into health. Comparable DTC motion with massive consumer reach, though predominantly array-based rather than WGS.
• Synlab / Labco: European clinical diagnostics giant where Veritas CEO Javier de Echevarría previously served as Chief Innovation Officer. Operates broad lab diagnostic services across Europe; relevant comparator for European scale and infrastructure.

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Veritas_Gen_EL
• YouTubeyoutube.com/channel/UCpvc5_GKq3453oqaQ83SwzQ
• Facebookfacebook.com/veritasgenetics
• LinkedInlinkedin.com/company/veritas-int
• Instagraminstagram.com/veritasgenetics_

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Veritas Intercontinental